Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Chronic Thalamic Stimulation for the Tremor of Multiple Sclerosis
Neurol 53:625-628, Montgomery,E.B.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses
Neurol 50:398-402, Achiron,A.,et al, 1998
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996